| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Endocrinology and Metabolism |
1
Diagnostic Science Division, Shionogi & Company, Ltd., 2-5-1 Mishima, Settsu-shi, Osaka 566, Japan.
2
Division of Cardiology, Kumamoto University of Medicine
School, Kumamoto 860, Japan.
3
Department of Medicine and Clinical Science, Kyoto
University Graduate School of Medicine, Kyoto 606, Japan.
a Author for correspondence. Fax 06-319-4109; e-mail yoshito.numata{at}shionogi.co.jp.
Recently, the N-terminal fragment of proatrial natriuretic peptide (N-terminal proANP) has been proposed as a marker of chronic congestive heart failure. In this study, we established a two-step immunoradiometric assay using monoclonal antibodies and synthetic N-terminal proANP (1–67) as a standard. It allows us to measure plasma N-terminal proANP in only 4 h without prior extraction. The detection limit of this assay was 15 pmol/L for a 100 µL sample of plasma. Within-run CVs ranged from 1.7% to 2.9% and between-run CVs ranged from 4.2% to 5.1%. The dilution curves of plasma samples showed good linearity and analytical recovery was 89–104%. The mean (±SD) N-terminal proANP in plasma of 33 healthy subjects was 188 (±71) pmol/L and 1030 (±411) pmol/L in 25 patients with heart failure. Our immunoradiometric assay is rapid and precise enough for routine determination of N-terminal proANP in human plasma.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  H. Wang, Y. Zhang, B. Yan, L. Liu, S. Wang, G. Shen, and R. Yu Rapid, Simple, and Sensitive Immunoagglutination Assay with SiO2 Particles and Quartz Crystal Microbalance for Quantifying Schistosoma japonicum Antibodies Clin. Chem., November 1, 2006; 52(11): 2065 - 2071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ala-Kopsala, J. Magga, K. Peuhkurinen, J. Leipala, H. Ruskoaho, J. Leppaluoto, and O. Vuolteenaho Molecular Heterogeneity Has a Major Impact on the Measurement of Circulating N-Terminal Fragments of A- and B-Type Natriuretic Peptides Clin. Chem., September 1, 2004; 50(9): 1576 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Morgenthaler, J. Struck, B. Thomas, and A. Bergmann Immunoluminometric Assay for the Midregion of Pro-Atrial Natriuretic Peptide in Human Plasma Clin. Chem., January 1, 2004; 50(1): 234 - 236. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Boomsma and A. H. van den Meiracker Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use Cardiovasc Res, August 15, 2001; 51(3): 442 - 449. [Full Text] [PDF]
|
|
|
|
|
|
A. Clerico, S. Del Ry, and D. Giannessi Measurement of Cardiac Natriuretic Hormones (Atrial Natriuretic Peptide, Brain Natriuretic Peptide, and Related Peptides) in Clinical Practice: The Need for a New Generation of Immunoassay Methods Clin. Chem., October 1, 2000; 46(10): 1529 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. De Palo, W. Woloszczuk, M. Meneghetti, C. B. De Palo, H. B. Nielsen, and N. H. Secher Circulating Immunoreactive proANP(1-30) and proANP(31-67) in Sedentary Subjects and Athletes Clin. Chem., June 1, 2000; 46(6): 843 - 847. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
